Opinion|Videos|October 11, 2024
Belimumab and Voclosporin: Clinical Insights and Payer Evaluations in Lupus Nephritis
Key Takeaways
- Belimumab and voclosporin have unique mechanisms of action, impacting their efficacy and safety profiles in lupus nephritis treatment.
- Payers consider clinical outcomes, cost, and value when evaluating belimumab and voclosporin for lupus nephritis management.
Panelists discuss the differences in efficacy and safety profiles between belimumab and voclosporin for lupus nephritis (LN) and how payers are evaluating their value, including considerations of cost-effectiveness in LN management.
Advertisement
Episodes in this series
What is your perspective on the differences between the efficacy and safety profiles of belimumab and voclosporin in the treatment of lupus nephritis (LN)? (Dr. Larranaga and Dr. Wells)
How are payers evaluating the value of belimumab and voclosporin in the management of LN? (Dr. Wigginton)
- What does cost-effectiveness look like in LN management?
Advertisement
Related Content
Advertisement
Advertisement
Advertisement
Trending on AJMC
1
CDC Officially Ends Hantavirus Response as Outbreak Risk Recedes
2
ATTR-CM Incidence, Prevalence Rose Sharply in the US
3
FDA Approves Palbociclib for HR+, HER2+ Breast Cancer Maintenance
4
Mixed Phase 3 Results for IB6-Targeting ADC Raise Questions on Optimal Use in NSCLC
5